BioMarin Pharmaceutical (BMRN) Competitors $57.74 -1.72 (-2.88%) As of 02:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BMRN vs. ALNY, BIIB, INCY, UTHR, NBIX, EXEL, EXAS, HALO, RGEN, and IONSShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Its Competitors Alnylam Pharmaceuticals Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis Exact Sciences Halozyme Therapeutics Repligen Ionis Pharmaceuticals BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Is BMRN or ALNY more profitable? BioMarin Pharmaceutical has a net margin of 21.45% compared to Alnylam Pharmaceuticals' net margin of -12.96%. BioMarin Pharmaceutical's return on equity of 12.59% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioMarin Pharmaceutical21.45% 12.59% 10.13% Alnylam Pharmaceuticals -12.96%-273.52%-7.39% Do institutionals & insiders hold more shares of BMRN or ALNY? 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.9% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend BMRN or ALNY? BioMarin Pharmaceutical presently has a consensus target price of $93.17, suggesting a potential upside of 61.35%. Alnylam Pharmaceuticals has a consensus target price of $403.92, suggesting a potential downside of 6.81%. Given BioMarin Pharmaceutical's higher possible upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioMarin Pharmaceutical 0 Sell rating(s) 6 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.75Alnylam Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 23 Buy rating(s) 0 Strong Buy rating(s) 2.85 Does the media favor BMRN or ALNY? In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 46 mentions for Alnylam Pharmaceuticals and 43 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.98 beat Alnylam Pharmaceuticals' score of 0.80 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 20 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, BMRN or ALNY? BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioMarin Pharmaceutical$2.85B3.88$426.86M$3.3717.14Alnylam Pharmaceuticals$2.25B25.27-$278.16M-$2.47-175.48 Which has more volatility & risk, BMRN or ALNY? BioMarin Pharmaceutical has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. SummaryBioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.94B$2.98B$5.46B$9.67BDividend YieldN/A2.46%3.99%4.14%P/E Ratio16.9217.9229.9924.97Price / Sales3.88174.22375.5577.11Price / Cash18.6941.8335.9458.58Price / Book1.847.308.165.68Net Income$426.86M-$54.43M$3.25B$265.38M7 Day Performance-0.68%0.07%1.11%2.52%1 Month Performance-0.42%5.24%2.80%1.86%1 Year Performance-34.31%10.72%28.49%24.21% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9941 of 5 stars$57.75-2.9%$93.17+61.4%-31.1%$10.94B$2.85B16.923,040Trending NewsAnalyst ForecastAnalyst RevisionALNYAlnylam Pharmaceuticals3.9122 of 5 stars$324.79-1.2%$347.75+7.1%+67.2%$42.35B$2.35B-155.402,230Analyst ForecastBIIBBiogen4.9121 of 5 stars$129.28-1.7%$186.37+44.2%-36.1%$18.94B$9.82B12.767,605INCYIncyte4.7701 of 5 stars$70.16-0.1%$74.47+6.1%+29.7%$13.58B$4.24B219.262,617Analyst UpgradeUTHRUnited Therapeutics4.9572 of 5 stars$298.14-2.1%$383.08+28.5%-7.1%$13.45B$2.99B11.901,305NBIXNeurocrine Biosciences4.9667 of 5 stars$133.71+1.2%$163.87+22.6%-12.9%$13.23B$2.36B45.331,800EXELExelixis4.9476 of 5 stars$44.39-2.7%$45.33+2.1%+41.0%$12.11B$2.17B20.181,147Positive NewsHigh Trading VolumeEXASExact Sciences4.7279 of 5 stars$48.04-0.9%$70.50+46.8%-22.9%$9.06B$2.83B-8.727,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHALOHalozyme Therapeutics4.7873 of 5 stars$57.73-0.9%$62.70+8.6%+14.7%$7.11B$1.08B15.35390News CoveragePositive NewsEarnings ReportAnalyst ForecastRGENRepligen4.8206 of 5 stars$119.65-1.7%$169.92+42.0%-30.1%$6.72B$634.44M-265.891,778IONSIonis Pharmaceuticals4.4945 of 5 stars$41.17-2.5%$55.67+35.2%-12.3%$6.55B$705M-13.771,069Insider TradeAnalyst Revision Related Companies and Tools Related Companies ALNY Competitors BIIB Competitors INCY Competitors UTHR Competitors NBIX Competitors EXEL Competitors EXAS Competitors HALO Competitors RGEN Competitors IONS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 While the market chops sideways and headlines dominate the news cycle, a small group of traders is quietly tak...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRN Stock Alerts